154 related articles for article (PubMed ID: 12441685)
21. PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.
Mahata S; Sahoo PK; Pal R; Sarkar S; Mistry T; Ghosh S; Nasare VD
Med Oncol; 2022 May; 39(5):74. PubMed ID: 35568774
[TBL] [Abstract][Full Text] [Related]
22. PDGF-BB promotes vascular smooth muscle cell migration by enhancing Pim-1 expression via inhibiting miR-214.
Zhou J; Shao L; Yu J; Huang J; Feng Q
Ann Transl Med; 2021 Dec; 9(23):1728. PubMed ID: 35071422
[TBL] [Abstract][Full Text] [Related]
23. An Updated Focus on Quadruplex Structures as Potential Therapeutic Targets in Cancer.
Sanchez-Martin V; Lopez-Pujante C; Soriano-Rodriguez M; Garcia-Salcedo JA
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255335
[TBL] [Abstract][Full Text] [Related]
24. PIM1 Promotes Survival of Cardiomyocytes by Upregulating c-Kit Protein Expression.
Ebeid DE; Firouzi F; Esquer CY; Navarrete JM; Wang BJ; Gude NA; Sussman MA
Cells; 2020 Aug; 9(9):. PubMed ID: 32878131
[TBL] [Abstract][Full Text] [Related]
25. Anti-Inflammatory Effects of the Novel PIM Kinase Inhibitor KMU-470 in RAW 264.7 Cells through the TLR4-NF-κB-NLRP3 Pathway.
Baek HS; Min HJ; Hong VS; Kwon TK; Park JW; Lee J; Kim S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698512
[TBL] [Abstract][Full Text] [Related]
26. Pim-1 Protects Retinal Ganglion Cells by Enhancing Their Regenerative Ability Following Optic Nerve Crush.
Zhang S; Shuai L; Wang D; Huang T; Yang S; Miao M; Liu F; Xu J
Exp Neurobiol; 2020 Jun; 29(3):249-272. PubMed ID: 32624507
[TBL] [Abstract][Full Text] [Related]
27. PIM-1 kinase: a potential biomarker of triple-negative breast cancer.
Chen J; Tang G
Onco Targets Ther; 2019; 12():6267-6273. PubMed ID: 31496730
[TBL] [Abstract][Full Text] [Related]
28. Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis.
Arrouchi H; Lakhlili W; Ibrahimi A
Bioinformation; 2019; 15(2):116-120. PubMed ID: 31435157
[TBL] [Abstract][Full Text] [Related]
29. Safety profiling of genetically engineered Pim-1 kinase overexpression for oncogenicity risk in human c-kit+ cardiac interstitial cells.
Broughton K; Korski K; Echeagaray O; Adamson R; Dembitsky W; Lu Z; Schaefer E; Sussman MA
Gene Ther; 2019 Aug; 26(7-8):324-337. PubMed ID: 31239537
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds.
Ikram N; Mirza MU; Vanmeert M; Froeyen M; Salo-Ahen OMH; Tahir M; Qazi A; Ahmad S
Biomolecules; 2019 Mar; 9(4):. PubMed ID: 30925835
[TBL] [Abstract][Full Text] [Related]
31. The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.
Stafman LL; Waldrop MG; Williams AP; Aye JM; Stewart JE; Mroczek-Musulman E; Yoon KJ; Whelan K; Beierle EA
J Pediatr Surg; 2019 Jun; 54(6):1206-1213. PubMed ID: 30898394
[TBL] [Abstract][Full Text] [Related]
32. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
33. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
[TBL] [Abstract][Full Text] [Related]
34. Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC).
Xu J; Zhu X; Li Q; Chen C; Guo Z; Tan Z; Zheng C; Ge M
Cancer Cell Int; 2018; 18():22. PubMed ID: 29467592
[TBL] [Abstract][Full Text] [Related]
35. High glucose promotes vascular smooth muscle cell proliferation by upregulating proto-oncogene serine/threonine-protein kinase Pim-1 expression.
Wang K; Deng X; Shen Z; Jia Y; Ding R; Li R; Liao X; Wang S; Ha Y; Kong Y; Wu Y; Guo J; Jie W
Oncotarget; 2017 Oct; 8(51):88320-88331. PubMed ID: 29179437
[TBL] [Abstract][Full Text] [Related]
36. PIM1: a promising target in patients with triple-negative breast cancer.
Zhao W; Qiu R; Li P; Yang J
Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
[TBL] [Abstract][Full Text] [Related]
37. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
38. PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311.
Yang J; Liu K; Yang J; Jin B; Chen H; Zhan X; Li Z; Wang L; Shen X; Li M; Yu W; Mao Z
Oncogene; 2017 Aug; 36(34):4828-4842. PubMed ID: 28394343
[TBL] [Abstract][Full Text] [Related]
39. A positive feedback loop between Pim-1 kinase and HBP1 transcription factor contributes to hydrogen peroxide-induced premature senescence and apoptosis.
Wang S; Cao Z; Xue J; Li H; Jiang W; Cheng Y; Li G; Zhang X
J Biol Chem; 2017 May; 292(20):8207-8222. PubMed ID: 28348080
[TBL] [Abstract][Full Text] [Related]
40. PIM1-minicircle as a therapeutic treatment for myocardial infarction.
Liu N; Wang BJ; Broughton KM; Alvarez R; Siddiqi S; Loaiza R; Nguyen N; Quijada P; Gude N; Sussman MA
PLoS One; 2017; 12(3):e0173963. PubMed ID: 28323876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
